These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21762222)

  • 1. A national audit of pollen immunotherapy for children in the United Kingdom: patient selection and programme safety.
    Vance GH; Goldring S; Warner JO; Cox H; Sihra B; Hughes S; Gardner J; North J; Roberts G; Proudfoot CA; Clarke A; Luyt DK; Gillies D; Fox AT
    Clin Exp Allergy; 2011 Sep; 41(9):1313-23. PubMed ID: 21762222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.
    Manzotti G; Pappacoda A; Dimatteo M; Scolari C; Riario-Sforza GG; Incorvaia C
    Eur Ann Allergy Clin Immunol; 2013 Aug; 45(4):138-43. PubMed ID: 24067339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
    Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
    Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
    J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An observational, real-life safety study of a 5-grass pollen sublingual tablet in children and adolescents.
    Eberle P; Brueck H; Gall R; Hadler M; Sieber J; Karagiannis E
    Pediatr Allergy Immunol; 2014 Dec; 25(8):760-6. PubMed ID: 25378225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
    Stelmach I; Kaczmarek-Woźniak J; Majak P; Olszowiec-Chlebna M; Jerzynska J
    Clin Exp Allergy; 2009 Mar; 39(3):401-8. PubMed ID: 19134016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous immunotherapy suppresses Th2 inflammation and induces neutralizing antibodies, but sublingual immunotherapy suppresses airway hyperresponsiveness in grass pollen mouse models for allergic asthma.
    Hesse L; Brouwer U; Petersen AH; Gras R; Bosman L; Brimnes J; Oude Elberink JNG; van Oosterhout AJM; Nawijn MC
    Clin Exp Allergy; 2018 Aug; 48(8):1035-1049. PubMed ID: 29752757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
    Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
    J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen.
    Wüthrich B; Bucher Ch; Jörg W; Bircher A; Eng P; Schneider Y; Schnyder F; Eigenmann P; Senti G
    J Investig Allergol Clin Immunol; 2003; 13(3):145-8. PubMed ID: 14635462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of allergen-specific immunotherapy (desensitization) for the treatment of allergies in Germany. Current situation].
    Kleine-Tebbe J; Ackermann-Simon J; Hanf G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Mar; 55(3):343-50. PubMed ID: 22373847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both sublingual and supralingual routes of administration are effective in long-term allergen-specific immunotherapy.
    Panzner P; Petráš M; Sýkora T; Lesná IK; Liška M
    Allergy Asthma Proc; 2011; 32(2):142-50. PubMed ID: 21439167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of AIT in children including potential to prevent the development of asthma.
    Valovirta E
    Allergy; 2011 Jul; 66 Suppl 95():53-4. PubMed ID: 21668856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy.
    Czarnecka-Operacz M; Jenerowicz D; Silny W
    Acta Dermatovenerol Croat; 2008; 16(1):19-24. PubMed ID: 18358104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One century of allergen-specific immunotherapy for respiratory allergy.
    Incorvaia C; Frati F
    Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013).
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    Ann Allergy Asthma Immunol; 2016 Apr; 116(4):354-359.e2. PubMed ID: 26948485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
    Wahn U; Klimek L; Ploszczuk A; Adelt T; Sandner B; Trebas-Pietras E; Eberle P; Bufe A;
    J Allergy Clin Immunol; 2012 Oct; 130(4):886-93.e5. PubMed ID: 22939758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life safety of 5-grass pollen tablet in 5-to-9-year-old children with allergic rhinoconjunctivitis.
    Gerstlauer M; Szepfalusi Z; Golden D; Geng B; de Blic J
    Ann Allergy Asthma Immunol; 2019 Jul; 123(1):70-80. PubMed ID: 31009701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.